Teva Pharmaceutical Industries Limited (TEVA) Reaches $23.66 After 4.00% Down Move; Profile of 2 Analysts Covering Falcon Oil & Gas Ltd. (CVE:FO)

June 14, 2018 - By Marguerite Chambers

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a huge mover today! The stock decreased 2.75% or $0.67 during the last trading session, reaching $23.66. About 8.76M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 22.74% since June 14, 2017 and is downtrending. It has underperformed by 35.31% the S&P500. Some Historical TEVA News: ; 03/05/2018 – TEVA PHARMACEUTICAL INDUSTRIES LTD – RESTRUCTURING PLAN ON-TRACK TO ACHIEVE $1.5 BLN OF SAVINGS IN 2018 AND $3.0 BLN BY END OF 2019; 15/05/2018 – BERKSHIRE TEVA STAKE UP 115% TO 40.5M ADRS AS OF 1Q; 06/03/2018 – TALK: TEVA PHARMACEUTICAL EUR 4Y 3.25%-3.5%, 7Y 4.5%-4.75%; 03/05/2018 – TEVA 1Q ADJ EPS 94C, EST. 67C; 15/05/2018 – TEVA: HALO EM TRIAL MET PRIMARY ENDPOINT; 28/03/2018 – Xenon Pharmaceuticals Confirms Closing of Transaction With Teva and Announces Preferred Shr Exchange Agreement With BVF Partners L.P; 13/03/2018 – Teva rebuffs EU pay-for-delay charge at hearing; 03/05/2018 – TEVA PHARM CEO SCHULTZ: MIGRAINE DRUG LIKELY TO BE APPROVED FOR QUARTERLY DOSAGE; 19/04/2018 – Teva and the Procter & Gamble Co Have Agreed to Terminate the PGT Healthcare Partnership; 27/04/2018 – TEVA PHARMACEUTICAL INDUSTRIES LTD – ADVERSE EVENTS WERE GENERALLY MILD AND CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF COPAXONEThe move comes after 9 months negative chart setup for the $24.10B company. It was reported on Jun, 14 by Barchart.com. We have $22.71 PT which if reached, will make NYSE:TEVA worth $963.88 million less.

Among 2 analysts covering Falcon Oil & Gas Ltd (CVE:FO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Falcon Oil & Gas Ltd had 5 analyst reports since August 27, 2015 according to SRatingsIntel. FinnCap maintained the shares of FO in report on Wednesday, October 7 with “Buy” rating. On Wednesday, September 2 the stock rating was maintained by FinnCap with “Buy”. The stock of Falcon Oil & Gas Ltd. (CVE:FO) has “Buy” rating given on Tuesday, September 1 by Cantor Fitzgerald. The stock of Falcon Oil & Gas Ltd. (CVE:FO) has “Buy” rating given on Tuesday, September 8 by Cantor Fitzgerald. See Falcon Oil & Gas Ltd. (CVE:FO) latest ratings:

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on August, 2. They expect $0.62 EPS, down 37.37% or $0.37 from last year’s $0.99 per share. TEVA’s profit will be $631.45 million for 9.54 P/E if the $0.62 EPS becomes a reality. After $0.91 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -31.87% negative EPS growth.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 157 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Tuesday, January 30 with “Sell” rating. The rating was downgraded by Bank of America on Monday, November 7 to “Neutral”. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Equal-Weight” rating given on Monday, May 7 by Morgan Stanley. The rating was maintained by RBC Capital Markets on Monday, October 30 with “Sell”. Barclays Capital maintained the stock with “Equal-Weight” rating in Wednesday, October 4 report. The rating was downgraded by Wells Fargo to “Market Perform” on Monday, January 9. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Neutral” rating by JP Morgan on Friday, January 20. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Buy” rating by Jefferies on Thursday, July 14. The company was maintained on Friday, April 7 by Oppenheimer. The company was maintained on Monday, July 27 by Standpoint Research.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Globes.Co.Il which released: “Tue: Teva rally fails to lift TASE” on June 12, 2018, also Globes.Co.Il with their article: “Teva well on the road to recovery” published on June 13, 2018, Globenewswire.com published: “Analysis: Positioning to Benefit within Teva Pharmaceutical Industries, Resonant, United Community Financial …” on June 07, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Globes.Co.Il and their article: “Sun: Resurgent Teva fails to lift flat TASE” published on June 10, 2018 as well as Seekingalpha.com‘s news article titled: “Buy Alibaba – Cramer’s Lightning Round (6/12/18)” with publication date: June 13, 2018.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $24.10 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

The stock increased 1.47% or $0.005 during the last trading session, reaching $0.345. About 20,000 shares traded. Falcon Oil & Gas Ltd. (CVE:FO) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Falcon Oil & Gas Ltd., an oil and gas company, engages in the acquisition, exploration, and development of unconventional and conventional gas and oil assets in Australia, Hungary, South Africa, and Canada. The company has market cap of $321.09 million. It holds interests in 3 exploration permits covering an area of approximately 1.4 million net acres in the Beetaloo Basin, Northern Territory, Australia. It currently has negative earnings. The firm also has a technical cooperation permit covering an area of approximately 7.5 million acres in the southwest Karoo Basin, South Africa; and production license covering an area of approximately 245,775 acres in the Makó Trough located in south-eastern Hungary.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marguerite Chambers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: